

What Is Claimed Is:

- 5 413
B1
1. An oligonucleotide 8 to 50 nucleotides in length which is targeted to mRNA encoding human raf and which is capable of inhibiting raf expression.
 2. The oligonucleotide of claim 1 which is targeted to mRNA encoding human A-raf.
 3. The oligonucleotide of claim 1 which is targeted to mRNA encoding human B-raf.
 - 10 4. The oligonucleotide of claim 1 which is targeted to mRNA encoding human c-raf.
 5. The oligonucleotide of claim 4 which is targeted to a translation initiation site, 3' untranslated region or 5' untranslated region of mRNA encoding human c-raf.
 - 15 6. The oligonucleotide of claim 1 which has at least one phosphorothioate linkage.
 7. The oligonucleotide of claim 1 wherein at least one of the nucleotide units of the oligonucleotide is modified at the 2' position of the sugar moiety.
 - 20 8. The oligonucleotide of claim 7 wherein said modification at the 2' position of the sugar moiety is a 2'-O-alkyl, a 2'-O-alkyl-O-alkyl or a 2'-fluoro modification.
 9. The oligonucleotide of claim 1 which is a chimeric oligonucleotide.
 - 25 10. A composition comprising the oligonucleotide of claim 1 and a pharmaceutically acceptable carrier.

11. The composition of claim 10 further comprising a chemotherapeutic agent.

12. A method of inhibiting the expression of human raf in human cells or tissues which express human raf comprising
5 contacting said human cells or tissues with the oligonucleotide of claim 1.

13. A method of treating or preventing a condition associated with the expression of human raf comprising administering to a human or cells thereof a therapeutically
10 effective amount of the oligonucleotide of claim 1.

14. The method of claim 13 wherein said expression of human raf is abnormal expression.

15. The method of claim 13 wherein said condition is a hyperproliferative condition.

16. The method of claim 15 wherein said hyperproliferative condition is cancer.

17. The method of claim 15 wherein said hyperproliferative condition is angiogenesis or neovascularization.

18. The method of claim 17 wherein said angiogenesis or neovascularization is ocular angiogenesis or neovascularization.

19. The method of claim 16 comprising administering the
25 oligonucleotide in combination with a chemotherapeutic agent.

20. A method of inhibiting hyperproliferation of cells comprising contacting hyperproliferating cells with the oligonucleotide of claim 1.

Year	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	